Skip to main content
. Author manuscript; available in PMC: 2023 Sep 29.
Published in final edited form as: Cell. 2022 Sep 29;185(20):3705–3719.e14. doi: 10.1016/j.cell.2022.09.007

Figure 1. Meropenem increased the incidence of intestinal GVHD in allo-HSCT patients and mice.

Figure 1.

(A) Incidence of intestinal GVHD in 295 allo-HSCT patients. Patients were stratified by antibiotic treatment from days -10 to 30 relative to allo-HSCT. (B) Experimental schema of murine GVHD model. Mice were treated with meropenem from days 3 to 15. TBI, total body irradiation. (C) Overall survival. Data are combined from three independent experiments. (D) H&E staining of histological sections of GVHD target organs collected on day 18. Bar, 100 μm. (E) GVHD histology scores of GVHD target organs harvested on day 18. All GVHD histology scores were quantified by a blinded pathologist. Combined data from two independent experiments are shown as means ± SEM. (F) Experimental schema of murine GVHD model. Mice were decontaminated with piperacillin/tazobactam plus nystatin from days 5 to 15. (G) Bacterial density of fecal samples collected from mice treated as indicated. Data are shown from one representative experiment. (H) Overall survival. Data are combined from three independent experiments.